The historical rank and industry rank for Silk Road Medical's PB Ratio or its related term are showing as below:
SILK'
s PB Ratio Range Over the Past 10 Years
Min: 1.71 Med: 16.15 Max: 33.72
Current: 5.63
During the past 7 years, Silk Road Medical's highest PB Ratio was 33.72. The lowest was 1.71. And the median was 16.15.
SILK's PB Ratio is ranked worse than 81.31% of 792
companies
in the Medical Devices & Instruments industry
Industry Median: 2.235
vs SILK: 5.63
During the past 12 months, Silk Road Medical's average Book Value Per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Silk Road Medical was 22.90% per year. The lowest was 7.10% per year. And the median was 15.00% per year.
Back to Basics: PB Ratio
Silk Road Medical PB Ratio Historical Data
The historical data trend for Silk Road Medical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's PB Ratio
For the Medical Devices subindustry, Silk Road Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's PB Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's PB Ratio falls into.
Silk Road Medical PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Silk Road Medical PB Ratio Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical (Silk Road Medical) Business Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your 